Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 70, Issue 20, Pages 3871-3882Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-013-1290-8
Keywords
Mesenchymal stem cells; Secretome; Neurodegenerative diseases; Neuroregeneration
Categories
Funding
- Portuguese Foundation for Science and Technology (FCT) [PTDC/SAU-BMA/114059/2009, SFRH/BD/69637/2010, SFRH/BD/51061/2010]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/51061/2010, SFRH/BD/69637/2010, PTDC/SAU-BMA/114059/2009] Funding Source: FCT
Ask authors/readers for more resources
The low regeneration potential of the central nervous system (CNS) represents a challenge for the development of new therapeutic strategies. Mesenchymal stem cells (MSCs) have been proposed as a possible therapeutic tool for CNS disorders. In addition to their differentiation potential, it is well accepted nowadays that their beneficial actions can also be mediated by their secretome. Indeed, it was already demonstrated, both in vitro and in vivo, that MSCs are able to secrete a broad range of neuroregulatory factors that promote an increase in neurogenesis, inhibition of apoptosis and glial scar formation, immunomodulation, angiogenesis, neuronal and glial cell survival, as well as relevant neuroprotective actions on different pathophysiological contexts. Considering their protective action in lesioned sites, MSCs' secretome might also improve the integration of local progenitor cells in neuroregeneration processes, opening a door for their future use as therapeutical strategies in human clinical trials. Thus, in this review we analyze the current understanding of MSCs secretome as a new paradigm for the treatment of CNS neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available